Andreas N. Saltos, MD

Andreas Saltos, MD, discusses the current space for patients with non-small cell lung cancer harbording EGFR and KRAS mutations.

Andreas Saltos, MD, discusses the key discoveries from a phase 1/1B trial of erlotinib and binimetinib in EGFR- and KRAS-mutated non–small cell lung cancer.

Andreas Saltos, MD, discusses what he anticipates future research will examine regarding treatment options for EGFR and KRAS-mutated non-small cell lung cancer.

Andreas Saltos, MD, discusses the key takeaways of the phase 1/1b clinical trial exploring the use of binimetinib plus erlotinib in patients with non–small cell lung cancer harboring either KRAS or EGFR mutations.

Andreas Saltos, MD, discusses a phase 1 trial of binimetinib and erlotinib for patients with non–small cell lung cancer and EGFR or KRAS mutations.